En español

A Pilot Study of Osmotic-Release Methylphenidate (OROS-MPH) in Initiating and Maintaining Abstinence in Smokers with Attention Deficit Hyperactivity Disorder (ADHD)

Cigarette in ash tray

The primary objective of this study was to evaluate whether OROS-MPH (Concerta), relative to placebo, increases the effectiveness of standard smoking treatment (i.e., nicotine patch and individual smoking cessation counseling) in obtaining prolonged abstinence for smokers with ADHD. The study involved 255 participants, recruited from six sites.

CTN Protocol ID: 
Enrollment Status: 
ClinicalTrials.gov ID: 
Primary Outcomes Article: 

Winhusen, T., et al. (2010).  Impact of attention-deficit/hyperactivity disorder (ADHD) treatment on smoking cessation intervention in ADHD smokers: a randomized, double-blind, placebo-controlled trial.  Journal of Clinical Psychiatry 71 (12): 1680-8.

Principal Investigator(s)
Eugene Somoza, M.D., Ph.D
University of Cincinnati/Cin ARC
3210 Jefferson Avenue, Suite 6
Cincinnati, OH 45220

Theresa Winhusen, Ph.D.
Professor of Psychiatry and Behavioral Neuroscience, Director of Addiction Sciences Division
University of Cincinnati
Addiction Sciences Division
3131 Harvey Avenue, Suite 104
Cincinnati, OH 45229-3006

Available Brochures

Get this Publication

    SAMHSA Treatment Locator

    Blending Initiative

    blending logo

    Formed with SAMHSA to reduce the gap between research results and treatment.